Pharmacogenetics and mood stabilization in bipolar disorder
- PMID: 14601033
- DOI: 10.1002/ajmg.c.20010
Pharmacogenetics and mood stabilization in bipolar disorder
Abstract
Bipolar disorder is a severe psychiatric disease characterized by varying treatment response among individual patients. Effects of certain treatments, for instance, lithium, can be predicted from clinical characteristics of patients and their family histories. This led to a suggestion that a treatment response could identify subtypes of bipolar disorder particularly suited for gene-mapping studies. In this paper we review family and molecular studies of bipolar disorder responsive to lithium, as well as studies aiming to identify polymorphisms associated with the treatment response itself. While molecular genetic research and gene expression studies promise to bring new insights into the pathophysiology of the illness and the nature of treatment response, and thus provide new information for better treatment of bipolar disorder in the future, results from family studies and studies of clinical correlates of treatment response may already be utilized in the management of bipolar disorder.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1038-45. doi: 10.1016/j.pnpbp.2005.03.021. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15946781 Review.
-
Pharmacogenetics of lithium response in bipolar disorder.J Psychiatry Neurosci. 1999 Mar;24(2):154-8. J Psychiatry Neurosci. 1999. PMID: 10212559 Free PMC article. Review.
-
A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder.Pharmacogenet Genomics. 2007 Aug;17(8):605-17. doi: 10.1097/FPC.0b013e328011b5b2. Pharmacogenet Genomics. 2007. PMID: 17622937
-
Pharmacogenetics and bipolar disorder.Pharmacogenomics J. 2004;4(3):161-70. doi: 10.1038/sj.tpj.6500245. Pharmacogenomics J. 2004. PMID: 15079146 Review.
-
[Predictors of prophylactic response to lithium].Encephale. 2008 Sep;34(4):394-9. doi: 10.1016/j.encep.2007.05.002. Epub 2007 Nov 26. Encephale. 2008. PMID: 18922242 Review. French.
Cited by
-
Hospital treatment, mortality and healthcare costs in relation to socioeconomic status among people with bipolar affective disorder.BJPsych Open. 2016 Jan 13;2(1):10-17. doi: 10.1192/bjpo.bp.115.000810. eCollection 2016 Jan. BJPsych Open. 2016. PMID: 27703748 Free PMC article.
-
Lithium: a key to the genetics of bipolar disorder.Genome Med. 2009 Aug 19;1(8):79. doi: 10.1186/gm79. Genome Med. 2009. PMID: 19691823 Free PMC article.
-
A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.BMC Syst Biol. 2010 Nov 19;4:158. doi: 10.1186/1752-0509-4-158. BMC Syst Biol. 2010. PMID: 21092101 Free PMC article.
-
Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder.Psychiatry Investig. 2008 Jun;5(2):102-5. doi: 10.4306/pi.2008.5.2.102. Epub 2008 Jun 30. Psychiatry Investig. 2008. PMID: 20046352 Free PMC article.
-
Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.CNS Drugs. 2009;23(4):331-49. doi: 10.2165/00023210-200923040-00005. CNS Drugs. 2009. PMID: 19374461 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical